145 related articles for article (PubMed ID: 38148609)
1. Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug-drug interactions.
Armani S; Geier A; Forst T; Merle U; Alpers DH; Lunnon MW
Br J Clin Pharmacol; 2024 Apr; 90(4):942-958. PubMed ID: 38148609
[TBL] [Abstract][Full Text] [Related]
2. Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.
Varma MV; El-Kattan AF
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S99-S109. PubMed ID: 27385183
[TBL] [Abstract][Full Text] [Related]
3. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
[TBL] [Abstract][Full Text] [Related]
4. Predictability of human pharmacokinetics of drugs that undergo hepatic organic anion transporting polypeptide (OATP)-mediated transport using single-species allometric scaling in chimeric mice with humanized liver: integration with hepatic drug metabolism.
Sanoh S; Naritomi Y; Kitamura S; Shinagawa A; Kakuni M; Tateno C; Ohta S
Xenobiotica; 2020 Nov; 50(11):1370-1379. PubMed ID: 32401667
[TBL] [Abstract][Full Text] [Related]
5. Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs.
Maeda K
Biol Pharm Bull; 2015; 38(2):155-68. PubMed ID: 25747975
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.
Shitara Y; Maeda K; Ikejiri K; Yoshida K; Horie T; Sugiyama Y
Biopharm Drug Dispos; 2013 Jan; 34(1):45-78. PubMed ID: 23115084
[TBL] [Abstract][Full Text] [Related]
7. [Role of transporters in hepatic drug disposition].
Gao CY; Chen XY; Zhong DF
Yao Xue Xue Bao; 2012 May; 47(5):565-72. PubMed ID: 22811997
[TBL] [Abstract][Full Text] [Related]
8. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
[TBL] [Abstract][Full Text] [Related]
9. Impact of OATP transporters on pharmacokinetics.
Kalliokoski A; Niemi M
Br J Pharmacol; 2009 Oct; 158(3):693-705. PubMed ID: 19785645
[TBL] [Abstract][Full Text] [Related]
10. Induction of Human Intestinal and Hepatic Organic Anion Transporting Polypeptides: Where Is the Evidence for Its Relevance in Drug-Drug Interactions?
Rodrigues AD; Lai Y; Shen H; Varma MVS; Rowland A; Oswald S
Drug Metab Dispos; 2020 Mar; 48(3):205-216. PubMed ID: 31879282
[TBL] [Abstract][Full Text] [Related]
11. Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity.
Cheng Q; Aleksunes LM; Manautou JE; Cherrington NJ; Scheffer GL; Yamasaki H; Slitt AL
Mol Pharm; 2008; 5(1):77-91. PubMed ID: 18189363
[TBL] [Abstract][Full Text] [Related]
12. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
13. Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions.
Alam K; Crowe A; Wang X; Zhang P; Ding K; Li L; Yue W
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29538325
[TBL] [Abstract][Full Text] [Related]
14. The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members.
Klatt S; Fromm MF; König J
Basic Clin Pharmacol Toxicol; 2013 Apr; 112(4):244-50. PubMed ID: 23121773
[TBL] [Abstract][Full Text] [Related]
15. Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.
Fahrmayr C; Fromm MF; König J
Drug Metab Rev; 2010 Aug; 42(3):380-401. PubMed ID: 20100011
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs.
Nakanishi T; Tamai I
Drug Metab Pharmacokinet; 2012; 27(1):106-21. PubMed ID: 22185815
[TBL] [Abstract][Full Text] [Related]
17. The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.
Fenner KS; Jones HM; Ullah M; Kempshall S; Dickins M; Lai Y; Morgan P; Barton HA
Xenobiotica; 2012 Jan; 42(1):28-45. PubMed ID: 22077101
[TBL] [Abstract][Full Text] [Related]
18. Drug transport proteins in the liver.
Faber KN; Müller M; Jansen PL
Adv Drug Deliv Rev; 2003 Jan; 55(1):107-24. PubMed ID: 12535576
[TBL] [Abstract][Full Text] [Related]
19. Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1.
Bachmakov I; Glaeser H; Fromm MF; König J
Diabetes; 2008 Jun; 57(6):1463-9. PubMed ID: 18314419
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic drug interactions in liver disease: An update.
Palatini P; De Martin S
World J Gastroenterol; 2016 Jan; 22(3):1260-78. PubMed ID: 26811663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
